When Amgen said it would hand over $13.4 billion for Celgene’s hit psoriasis drug Otezla in August, analysts agreed it had overpaid by $2 billion. But they also predicted Amgen’s […]
Sanofi CEO Paul Hudson has been on the job for just over two months, and he’s prepping for a big strategy reveal next month. One thing that might be behind […]
Shares in The Medicines Company have leapt on rumours that Novartis is eyeing a takeover of the company and its promising new cardiovascular drug inclisiran. A report from Bloomberg also […]
The drug patent system was created to reward pharma companies for innovation and ensure returns on investment, but increasingly companies are manipulating the system using techniques like ‘evergreening’ and ‘thicketing’ […]
Amgen’s top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East Coast last […]
